Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity disorder ...

But this month, Cingulate was able to reinstate those executives’ annual base salaries. CEO Shane Schaffer’s annual base salary is back to $503,000, COO Laurie Myer’s salary is $424,000, and ...

At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading. According to the Kansas-based biotech, children who took CTx-1301 at doses of 18 ...

Using Catalent's capabilities, Cingulate believes its two drugs can address long-standing unmet needs in ADHD treatment. CTX-1301, its most advanced candidate, ...

Cingulate Inc. (NASDAQ:CING) shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the ...

According to Cingulate, the extended-release drugs account for 85% of sales of stimulants in ADHD. Cingulate is betting it can take a slice of those sales by improving on the delivery of the ...

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its ...

It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301, which is designed to treat Attention Deficit Hyperactivity Disorder (ADHD).

The Kansas City, Kansas-based pharmaceutical startup has worked its way through a couple of delisting warnings from the Nasdaq stock exchange. Cingulate loses key execs, almost its entire board ...